UFP-101 TFA is primarily utilized in research settings as a selective antagonist for the nociceptin/orphanin FQ (NOP) receptor. Its application is significant in the study of pain modulation, anxiety, and addiction mechanisms, providing insights into the role of the NOP receptor in these processes. Researchers employ UFP-101 TFA to investigate potential therapeutic targets for managing chronic pain and developing treatments for substance abuse disorders. Additionally, it is used in preclinical studies to explore its effects on stress-related behaviors and emotional regulation, contributing to advancements in neuropharmacology.